• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.呼吸道合胞病毒（RSV）和3型副流感病毒（PIV3）疫苗研发的现状：世界卫生组织/美国国立过敏和传染病研究所联合会议纪要
Bull World Health Organ. 1997;75(4):307-13.
2
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.通过导入呼吸道合胞病毒cpts530L聚合酶突变，增强了重组人副流感病毒3型cp45候选疫苗病毒的减毒效果。
Virology. 1999 Jul 20;260(1):125-35. doi: 10.1006/viro.1999.9802.
3
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.一项在血清阴性儿童中研究活减毒呼吸道合胞病毒和副流感病毒 3 型疫苗的安全性和免疫原性的 1 期研究。
Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.
4
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.婴幼儿呼吸道合胞病毒与副流感病毒3型联合减毒活疫苗的评估
J Infect Dis. 2004 Dec 15;190(12):2096-103. doi: 10.1086/425981. Epub 2004 Nov 8.
5
Current approaches to the development of vaccines effective against parainfluenza viruses.开发有效抗副流感病毒疫苗的当前方法。
Bull World Health Organ. 1988;66(3):391-7.
6
Current status of vaccines for parainfluenza virus infections.副流感病毒感染疫苗的现状
Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f.
7
Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.呼吸道合胞病毒（RSV）F 蛋白表达的遗传稳定性和人肺细胞内传代致弱后，活减毒 PIV3 载体 RSV 候选疫苗（MEDI-534）的受限生长表型。
Vaccine. 2013 Aug 12;31(36):3756-62. doi: 10.1016/j.vaccine.2013.04.015. Epub 2013 Apr 24.
8
Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.在对活减副流感 3 型病毒载体 RSV 疫苗 MEDI-534 的 1 期评估中观察到呼吸道合胞病毒（RSV）F 转基因序列异质性的意义。
Vaccine. 2013 Jun 10;31(26):2822-7. doi: 10.1016/j.vaccine.2013.04.006. Epub 2013 Apr 16.
9
Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.
Vaccine. 1995 Mar;13(4):415-21. doi: 10.1016/0264-410x(95)98266-d.
10
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.呼吸道合胞病毒和副流感病毒的减毒活病毒疫苗：反向遗传学的应用
J Clin Invest. 2002 Jul;110(1):21-7. doi: 10.1172/JCI16077.

引用本文的文献

1
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.对已获许可的病毒疫苗、其中一些安全性问题以及研究性病毒疫苗开发进展的综述。
J Infect. 2004 Oct;49(3):179-209. doi: 10.1016/j.jinf.2004.05.018.
2
Respiratory syncytial virus genetic and antigenic diversity.呼吸道合胞病毒的基因和抗原多样性。
Clin Microbiol Rev. 2000 Jan;13(1):1-15, table of contents. doi: 10.1128/CMR.13.1.1.
3
Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.副流感病毒感染的流行病学特征：1975 - 1997年英格兰和威尔士的实验室监测
Eur J Epidemiol. 1999 May;15(5):475-84. doi: 10.1023/a:1007511018330.
4
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.人对呼吸道合胞病毒感染中病毒包膜成熟和未成熟形式的抗体反应：对亚单位疫苗的意义。
J Virol. 1999 Apr;73(4):2956-62. doi: 10.1128/JVI.73.4.2956-2962.1999.

呼吸道合胞病毒（RSV）和3型副流感病毒（PIV3）疫苗研发的现状：世界卫生组织/美国国立过敏和传染病研究所联合会议纪要

Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.

作者信息

Murphy B R, Collins P L

机构信息

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases NIH, Bethesda, MD, USA.

出版信息

Bull World Health Organ. 1997;75(4):307-13.

PMID:9342889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2486968/
Abstract

A Joint WHO/National Institute of Allergy and Infectious Diseases (NIAID) meeting on the current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development was held in Bethesda, MD, from 30 September to 1 October 1996. The meeting summarized the worldwide impact of RSV and PIV3; presented the current status of development of RSV and PIV3 vaccines; and examined the applications of recombinant DNA technology to the development and characterization of vaccines and to the understanding of viral pathogenesis.

摘要

1996年9月30日至10月1日，世界卫生组织（WHO）与美国国立过敏和传染病研究所（NIAID）就呼吸道合胞病毒（RSV）和3型副流感病毒（PIV3）疫苗研发的现状举行了一次联合会议。会议总结了RSV和PIV3在全球范围内的影响；介绍了RSV和PIV3疫苗的研发现状；并探讨了重组DNA技术在疫苗研发与特性分析以及理解病毒发病机制方面的应用。